Literature DB >> 26538633

Food Restriction Ameliorates the Development of Polycystic Kidney Disease.

Gina Warner1, Kyaw Zaw Hein1, Veronica Nin1, Marika Edwards1, Claudia C S Chini2, Katharina Hopp3, Peter C Harris3, Vicente E Torres3, Eduardo N Chini2.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the accumulation of kidney cysts that ultimately leads to loss of renal function and kidney failure. At present, the treatment for ADPKD is largely supportive. Multiple studies have focused on pharmacologic approaches to slow the development of the cystic disease; however, little is known about the role of nutrition and dietary manipulation in PKD. Here, we show that food restriction (FR) effectively slows the course of the disease in mouse models of ADPKD. Mild to moderate (10%-40%) FR reduced cyst area, renal fibrosis, inflammation, and injury in a dose-dependent manner. Molecular and biochemical studies in these mice indicate that FR ameliorates ADPKD through a mechanism involving suppression of the mammalian target of the rapamycin pathway and activation of the liver kinase B1/AMP-activated protein kinase pathway. Our data suggest that dietary interventions such as FR, or treatment that mimics the effects of such interventions, may be potential and novel preventive and therapeutic options for patients with ADPKD.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; AMPK; mTOR; metabolism; nutrition; polycystic kidney disease

Mesh:

Substances:

Year:  2015        PMID: 26538633      PMCID: PMC4849816          DOI: 10.1681/ASN.2015020132

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  35 in total

Review 1.  Aging and survival: the genetics of life span extension by dietary restriction.

Authors:  William Mair; Andrew Dillin
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

2.  Food restriction retards body growth and prevents end-stage renal pathology in remnant kidneys of rats regardless of protein intake.

Authors:  D C Tapp; W G Wortham; J F Addison; D N Hammonds; J L Barnes; M A Venkatachalam
Journal:  Lab Invest       Date:  1989-02       Impact factor: 5.662

Review 3.  The CALERIE Study: design and methods of an innovative 25% caloric restriction intervention.

Authors:  Amy D Rickman; Donald A Williamson; Corby K Martin; Cheryl H Gilhooly; Richard I Stein; Connie W Bales; Susan Roberts; Sai Krupa Das
Journal:  Contemp Clin Trials       Date:  2011-07-08       Impact factor: 2.226

4.  Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP.

Authors:  R Mangoo-Karim; M Uchic; C Lechene; J J Grantham
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.

Authors:  Li Chen; Xia Zhou; Lucy X Fan; Ying Yao; Katherine I Swenson-Fields; Mihaela Gadjeva; Darren P Wallace; Dorien J M Peters; Alan Yu; Jared J Grantham; Xiaogang Li
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

6.  Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.

Authors:  S E Dunn; F W Kari; J French; J R Leininger; G Travlos; R Wilson; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 7.  mTOR signaling in polycystic kidney disease.

Authors:  Oxana Ibraghimov-Beskrovnaya; Thomas A Natoli
Journal:  Trends Mol Med       Date:  2011-07-19       Impact factor: 11.951

8.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

9.  SIRT1 but not its increased expression is essential for lifespan extension in caloric-restricted mice.

Authors:  Evi M Mercken; Jia Hu; Susan Krzysik-Walker; Min Wei; Ying Li; Michael W McBurney; Rafael de Cabo; Valter D Longo
Journal:  Aging Cell       Date:  2013-11-19       Impact factor: 9.304

10.  Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

Authors:  Isaline Rowe; Marco Chiaravalli; Valeria Mannella; Valeria Ulisse; Giacomo Quilici; Monika Pema; Xuewen W Song; Hangxue Xu; Silvia Mari; Feng Qian; York Pei; Giovanna Musco; Alessandra Boletta
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

View more
  64 in total

1.  Slowing Polycystic Kidney Disease by Fasting.

Authors:  Alessandra Boletta
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

2.  Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2018-01-03       Impact factor: 8.860

Review 3.  Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.

Authors:  Wouter N Leonhard; Hester Happe; Dorien J M Peters
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

Review 4.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

Review 5.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

Review 6.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

7.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

8.  Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.

Authors:  Sonu Kashyap; Kyaw Zaw Hein; Claudia Cs Chini; Jorgo Lika; Gina M Warner; Laurie K Bale; Vicente E Torres; Peter C Harris; Claus Oxvig; Cheryl A Conover; Eduardo N Chini
Journal:  JCI Insight       Date:  2020-02-27

9.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

10.  Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Zhiying You; Berenice Gitomer; Godela Brosnahan; Vicente E Torres; Arlene B Chapman; Ronald D Perrone; Theodore I Steinman; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Alan S L Yu; Peter C Harris; Kyongtae T Bae; Marie Hogan; Dana Miskulin; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2017-11-08       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.